Acc Consensus On New Diabetes Drugs To Reduce Cv Outcomes | Latest News RSS feed

Acc Consensus On New Diabetes Drugs To Reduce Cv Outcomes - Latest News


ACC Consensus on New Diabetes Drugs to Reduce CV Outcomes

The American College of Cardiology has issued an Expert Consensus Decision Pathway aimed at educating cardiologists on the use of two major new classes of diabetes drugs — sodium-glucose cotransporter ... read more

Consider CV-Prevention Diabetes Drugs At Cardiology Visits, ACC Says

Cardiologists should consider adding a glucose-lowering drug proven to have cardiovascular benefits for all their type 2 diabetes (T2D ... diagnosed with T2D. Expert Consensus Decision Pathways are ... read more

Relationship Between Heart Failure and Diabetes Seen Throughout ACC Sessions

More than a decade after an FDA mandate for cardiovascular ... failure and diabetes, and updated primary prevention guidelines that boost 2 drug classes shown to reduce heart failure hospitalization. ... read more

Looking for another news?


Clear Consensus—Treat Cardiovascular Disease Concurrent with Diabetes

1 The American College of Cardiology issued an expert consensus ... can directly improve cardiovascular outcomes. In large-well-conducted, randomized clinical trials, specific medications in these two ... read more


Heart Data on Diabetes Drugs Leading to New Guidance

To frame the situation, traditionally speaking, we've viewed diabetes drugs as therapies to lower ... The ACC has an upcoming expert consensus decision pathway document focusing exactly on the when, ... read more

ACC recommends empagliflozin as preferred SGLT2 inhibitor for adults with type 2 diabetes

The 2018 ACC Expert Consensus statement emphasizes the need for a collaborative treatment approach by healthcare providers to reduce cardiovascular ... care and outcomes of people with type 2 diabetes ... read more

ACC: AstraZeneca's Farxiga chops follow-up CV events by 16% in heart attack patients with diabetes

Both analyses were released Monday at the American College of Cardiology meeting in New Orleans, and were based on data drawn from Declare, an outcomes ... lower risk of cardiovascular events for ... read more

A Paradigm Shift Highlights the Need to Reduce CV Risk in Diabetes

Given the discovery in recent years that diabetes medications ... the American College of Cardiology (ACC) endorsed a chapter on cardiovascular disease and diabetes care, just weeks after the ADA had ... read more

For 2019, ADA and ACC Align Their Diabetes Recommendations

The "expert consensus decision pathway" in the cardiovascular disease management section of the new ... reduce adverse cardiovascular outcomes in patients with cardiovascular disease and diabetes. ... read more

Certain SGLT2 Inhibitors, GLP-1 RAs for T2DM Also Cut CV Risk

The authors note that specific medications in these classes can reduce rates of acute myocardial ... algorithms proposed here will change as new evidence emerges, but that the overarching goal of ... read more

Amarin’s Vascepa nabs ADA backing to cut heart risks, even ahead of FDA review

The cardiovascular outcomes results Amarin rolled out ... Just last week at the American College of Cardiology annual meeting, Amarin unveiled new data from the same Reduce-It study, showing Vascepa ... read more



FeedsRSS Created by. Full RSS Feed | Privacy Policy | Contact Us